Thrombin as an anticoagulant.

摘要: Thrombosis is the most prevalent cause of fatal diseases in developed countries. An antithrombotic agent that can be administered to patients with severe acute thrombotic without risk causing hemorrhage, as experienced antithrombotic/thrombolytic therapy treatment ischemic stroke or systemic anticoagulants like heparin, would likely revolutionize cardiovascular and cerebrovascular diseases. Thrombin remains at forefront medicine a major target anticoagulant therapies, due its involvement deaths. Heparins direct thrombin inhibitors currently used complications, especially venous circulation, are plagued by complications related dosage bleeding. A new strategy intervention has been proposed recent years aiming modulating, rather than inhibiting, function. Specifically, efforts have directed toward finding ways exploiting function unleashed activation protein C, either using small modulators engineering. The ability activate C coexists procoagulant prothrombotic functions, mediated respectively cleavage fibrinogen protease-activated receptor 1 (PAR1). inhibits active site abrogates but also shuts down activity C. On other hand, selectively compromises PAR1 recognition may take advantage cytoprotective functions activated prove interest for vivo applications. This chapter summarizes current engineering convert into potent safe